burden of disease

Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease

Curigliano G, Hu X, Dent R, Yonemori K, Barrios CH, Pierga JY, Puglisi F, Ferrero JM, Jung KH, Bagegni NA, Collignon J, Gil-Gil M, Wu[...]

By afschroeder • March 5, 2026

Patient-Identified Treatment Goals for Psoriatic Disease: Results From a US Patient Survey

Armstrong A, Levit NA, Schneider B, Seiden R, Shi L, Kaplan B, Wu JJ. Patient-Identified Treatment Goals for Psoriatic Disease: Results From a US Patient[...]

By sjmartinez • November 15, 2024